MXPA03001484A - Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof. - Google Patents

Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof.

Info

Publication number
MXPA03001484A
MXPA03001484A MXPA03001484A MXPA03001484A MXPA03001484A MX PA03001484 A MXPA03001484 A MX PA03001484A MX PA03001484 A MXPA03001484 A MX PA03001484A MX PA03001484 A MXPA03001484 A MX PA03001484A MX PA03001484 A MXPA03001484 A MX PA03001484A
Authority
MX
Mexico
Prior art keywords
quinazolines
medicaments
compounds
contain
effective
Prior art date
Application number
MXPA03001484A
Other languages
Spanish (es)
Inventor
Stefan Blech
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of MXPA03001484A publication Critical patent/MXPA03001484A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
MXPA03001484A 2000-08-26 2001-08-18 Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof. MXPA03001484A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10042064A DE10042064A1 (en) 2000-08-26 2000-08-26 Chinazolines, medicaments containing these compounds, their use and processes for their preparation
PCT/EP2001/009534 WO2002018375A1 (en) 2000-08-26 2001-08-18 Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof

Publications (1)

Publication Number Publication Date
MXPA03001484A true MXPA03001484A (en) 2003-06-06

Family

ID=7653950

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03001484A MXPA03001484A (en) 2000-08-26 2001-08-18 Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof.

Country Status (7)

Country Link
EP (1) EP1322645A2 (en)
JP (1) JP2004507537A (en)
AU (1) AU2002210444A1 (en)
CA (1) CA2417955A1 (en)
DE (1) DE10042064A1 (en)
MX (1) MXPA03001484A (en)
WO (1) WO2002018375A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EE04748B1 (en) 1999-06-21 2006-12-15 Boehringer Ingelheim Pharma Kg Bicyclic heterocyclic compounds, drugs containing these compounds, their use and methods for their preparation
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (en) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Use of inhibitors of EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH) / prostatic hypertrophy
FR2853650B1 (en) * 2003-04-10 2006-07-07 Merck Sante Sas AMINE DEDOUBLING PROCESS USEFUL FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH INSULINO-RESISTANCE SYNDROME
WO2007055513A1 (en) * 2005-11-08 2007-05-18 Hanmi Pharm. Co., Ltd. Quinazoline derivatives as a signal transduction inhibitor and method for the preparation thereof
KR100832593B1 (en) * 2005-11-08 2008-05-27 한미약품 주식회사 Quinazoline derivatives as an signal trnasduction inhibitor and method for the preparation thereof
EP1948179A1 (en) 2005-11-11 2008-07-30 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
SI2068880T1 (en) 2006-09-18 2012-08-31 Boehringer Ingelheim Int Method for treating cancer harboring egfr mutations
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
HUE044629T2 (en) 2009-07-06 2019-11-28 Boehringer Ingelheim Int Process for drying of bibw2992, of its salts and of solid pharmaceutical formulations comprising this active ingredient
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US20190112317A1 (en) 2015-10-05 2019-04-18 The Trustees Of Columbia University In The City Of New York Activators of autophagic flux and phospholipase d and clearance of protein aggregates including tau and treatment of proteinopathies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9708640B1 (en) * 1996-04-12 2013-06-11 irreversible tyrosine kinase inhibitors and pharmaceutical composition comprising them.
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
BR9915487A (en) * 1998-11-19 2001-07-31 Warner Lambert Co N- [4- (3-chloro-4-fluoro-phenylamino) - 7 - (3-morpholin-4-yl-propoxy) -quinazolin-6-yl] -acrylamide, an irreversible inhibitor of tyrosine kinases
ID29800A (en) * 1999-02-27 2001-10-11 Boehringer Ingelheim Pharma 4-AMINO-KINAZOLIN AND KINOLIN DISTRICTS THAT HAVE INHIBITOR EFFECTS ON SIGNAL TRANSDUKSI MEDIUMED BY THYROSIN KINASE

Also Published As

Publication number Publication date
EP1322645A2 (en) 2003-07-02
WO2002018375A1 (en) 2002-03-07
JP2004507537A (en) 2004-03-11
DE10042064A1 (en) 2002-03-07
AU2002210444A1 (en) 2002-03-13
CA2417955A1 (en) 2003-01-30

Similar Documents

Publication Publication Date Title
MXPA03000873A (en) Quinazoline derivatives, medicaments containing these compounds, their use, and methods for the production thereof.
MXPA03008690A (en) Novel tyrosine kinase inhibitors.
HUS1400005I1 (en) Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
ZA200202985B (en) Tyrosine kinase inhibitors.
ZA200206386B (en) Kinase inhibitors.
AP2005003452A0 (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors.
DZ3186A1 (en) Pteridinones used as kinase inhibitors.
NL300242I1 (en) Mega-carboxyaryl substituted diphenylureas as well as kinase inhibitors.
MXPA03002297A (en) Triazole compounds useful as protein kinase inhibitors.
ZA200502247B (en) Selected CGRP antagonists, method for production and use thereof as medicament.
IL152754A0 (en) Quinazoline derivatives for the treatment of tumours
HK1049154A1 (en) 2-pyrazolin-5-ones as tyrosine kinase inhibitors
MXPA03001483A (en) Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof.
IL159120A0 (en) Cdk inhibiting pyrimidines, production thereof and their use as medicaments
ZA200301813B (en) Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them.
AP2003002857A0 (en) New spirotricyclic derivatives and their use as phosphodiesterase-7 inhibitors.
AU2002219174A1 (en) Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
HK1048813A1 (en) Indazole compounds and pharmaceutical compositionsfor inhibiting protein kinases, and methods for their use.
IL157109A0 (en) Quinazolines as mmp-13 inhibitors
AP2005003353A0 (en) Diazepinoindole derivatives as kinase inhibitors.
MXPA03009847A (en) Pyrazole derived kinase inhibitors.
EG24957A (en) Quinazoline derivatives as src tyrosine kinase inhibitors.
MXPA03001777A (en) Quinazoline derivatives as alpha-1 adrenergic antagonists.
HK1053839A1 (en) Novel 7-azaindoles, use thereof as phosphodiesterase 4 inhibitors and method for producing the same.
MXPA03001484A (en) Quinazolines, medicaments, which contain these compounds and which are effective as tyrosine kinase inhibitors, their use, and methods for the production thereof.